Physician profile
Scott A Asher
NPI 1316109978
$2,365.09
in general payments reported to CMS, 2019-2025
14 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Plastic Surgery Within The Head and Neck provider received nationally (typical 2025 total: $300).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $31.50 · 2021: $268 · 2022: $202 · 2023: $452 · 2024: $654 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,562.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $663.86 | 2023-2025 | Botox, Natrelle Saline-Filled Breast Implants |
| Galderma Laboratories, L.P. | $306.82 | 2019-2024 | Dysport |
| Organogenesis INC. | $288.11 | 2022-2024 | Puraply |
| Allergan, INC. | $281.41 | 2019-2022 | |
| Revance Therapeutics, INC. | $238.54 | 2024-2025 | Daxxify |
| Merz North America, INC. | $121.77 | 2019-2024 | |
| Mentor Worldwide LLC | $115.41 | 2021-2024 | Mentor Memorygel Resterilizable Gel Sizer |
| Regeneron Healthcare Solutions, INC. | $89.58 | 2019 | |
| Kerecis Limited | $68.25 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Pacira Pharmaceuticals Incorporated | $47.06 | 2022-2023 | Exparel |
| Davol INC. | $46.74 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $45.78 | 2023 | Seglentis |
| Genzyme Corporation | $31.50 | 2020 | |
| Leo Pharma INC. | $20.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Asher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.